Siglecs -which are sialic acid-binding immunoglobulinlike lectins -were discovered through converging studies on sialoadhesin (also known as Siglec-1 and CD169) and CD22 (also known as Siglec-2). Sialoadhesin was initially defined as a macrophage adhesion receptor recognizing sialic acids and was then shown to be a member of the immunoglobulin (Ig) superfamily, whereas CD22 was characterized as a B cell inhibitory receptor of the Ig superfamily that was later shown to recognize sialic acids 1,2 . The homology of these proteins with CD33 (also known as Siglec-3) and myelin-associated glycoprotein (MAG; also known as Siglec-4) led to the establishment of the Siglec family; to date, 14 Siglecs have been identified in humans and nine in mice 3 (TABLE 1) .
Siglecs can be divided into two groups: those that are conserved across mammals -such as sialoadhesin, CD22, MAG and Siglec-15 -and a group of CD33-related Siglecs that are variable across mammals. The CD33-related Siglecs are thought to have expanded from a primordial cluster of SIGLEC genes that underwent an inverse duplication event more than 180 million years ago 4 . Humans and many other mammals express a much larger set of CD33-related Siglecs than mice and rats, which can be explained by a dramatic loss of Siglec genes in rodents 4 . Similar to many other members of the Ig superfamily, Siglecs are cell-surface transmembrane receptors that are comprised of 2-17 extracellular Ig domains, including an amino-terminal V-set domain that contains the sialic acid-binding site 3 (TABLE 1) . The cytoplasmic domains of most Siglecs have immuno receptor tyrosine-based inhibitory motifs (ITIMs) and signal negatively via the recruitment of tyrosine phosphatases such as the SH2 domaincontaining protein tyrosine phosphatases SHP1 and SHP2
(also known as PTPN6 and PTPN11, respectively) 3 . A few Siglecs -such as Siglec-14, Siglec-15
and Siglec-16 -associate with the immunoreceptor tyrosine-based activation motif (ITAM) adaptor DAP12 (also known as TYROBP) via a positively charged amino acid in their transmembrane region (TABLE 1) and these are predicted to be activating receptors through the recruitment of spleen tyrosine kinase (SYK). Interestingly, most humans express two pairs of Siglecs that share nearly identical extracellular ligandbinding regions, but that have divergent transmembrane and cytoplasmic regions. For example, the ITIMcontaining Siglec-5 and Siglec-11 are paired with the DAP12-coupled Siglec-14 and Siglec- 16, respectively 3 . The evolution of these activating receptors from their corresponding inhibitory receptors is thought to have been driven by pathogen exploitation of the inhibitory Siglecs and thereby provides the host with additional activatory pathways to combat these pathogens [5] [6] [7] [8] . Most, if not all, Siglecs are also endocytic receptors that either constitutively cycle between the cell surface and intracellular endosomes, or are induced to undergo endocytosis upon ligation by antibody or multivalent ligands 3, [9] [10] [11] [12] [13] [14] [15] . However, the mechanisms of endocytosis vary, with some that are clathrin dependent, and others that are not 12, 13, 15 . Similarly, whereas the cytoplasmic tyrosinebased motifs are implicated in regulating the endocytosis of some Siglecs 9, 13, 14 , sialoadhesin has no known regulatory motifs yet undergoes efficient endocytosis and can carry ligand-bearing cargo into the cell [9] [10] [11] 14 . Crystal structures of the N-terminal regions of sialoadhesin, Siglec-5 and Siglec-7 in complex with various sialic acid ligands have revealed the molecular basis for specificity [16] [17] [18] . Most Siglecs are preferentially C. jejuni, Campylobacter jejuni; COPD, chronic obstructive pulmonary disease, DC, dendritic cell; GBS, group B Streptococcus; GRB2, growth factor receptor-bound protein 2; Ig, immunoglobulin; ITIM, immunoreceptor tyrosine-based inhibitory motif; MAG, myelin-associated glycoprotein; NK, natural killer; PRRSV, porcine reproductive and respiratory syndrome virus; SLE, systemic lupus erythematosus. *Two additional Siglec genes and proteins are found in chimpanzees that are either only expressed in some humans in a form that does not bind sialic acids (in the case of Siglec-12) or they have been deleted from the human genome (in the case of Siglec-13) 147, 148 . ‡ Specificities are summarized from the cited references or from glycan array data on the Functional Glycomics Gateway website. Sialoside structures are shown in diagrammatical form showing linkages (indicated by αX and βX, where X is number) between the following residues: N-acetylneuraminic acid (purple diamond), N-glycolyl-neuraminic acid (light blue diamond), galactose (yellow circle), N-acetylgalactosamine (yellow square), N-acetylglucosamine (dark blue square), fucose (red triangle). Sulphation is indicated by 'S'. § Disease relevance is based on animal models or expression on cell types that are involved in disease processes. Additional references for disease relevance are cited in the main text.
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Conserved tyrosine of unknown function.
Immunoreceptor tyrosinebased inhibitory motifs (ITIMs). Short peptide motifs containing tyrosine residues that are found in the cytoplasmic regions of many inhibitory receptors. These motifs are phosphorylated after receptor activation, often by SRC family protein-tyrosine kinases, which produces a binding site for cytoplasmic phosphatases and other signalling molecules, resulting in the dephosphorylation of activation complexes and inhibition of signalling cascades.
SHP1 and SHP2
SH2 domain-containing phosphatases that bind phosphorylated immunoreceptor tyrosine-based inhibitory motifs. The recruitment of SHP1 and SHP2 by Siglecs represents a general mechanism for modulation of immune cell signalling.
Immunoreceptor tyrosine-based activation motif (ITAM). A short peptide motif containing tyrosine residues that is found in the cytoplasmic tails of several signalling molecules and in adaptors such as DAP12. The tyrosine is phosphorylated after receptor activation and triggers a cascade of intracellular events that typically results in cellular activation.
expressed by specific cell types, which results in a complex and partially overlapping expression pattern within the innate and adaptive immune systems (TABLE 1) . Therefore, the role of different Siglecs in a disease context is determined to a large extent by their expression patterns and the relative importance of different cell populations to the specific disease. Several poly morphisms in the genes encoding Siglecs have been linked to human diseases, in particular, those in CD33, SIGLEC8 and SIGLEC14, which are discussed further below.
Each Siglec has a distinct preference for binding the diverse types of sialylated glycans that are found on the surface of mammalian cells (TABLE 1) . These binding preferences have been revealed by a variety of methods, including glycan array analyses 3 . As sialic acids are present on all cells, the glycan ligands of Siglecs are effectively markers of 'self ' . Not surprisingly, the interactions of Siglecs with their ligands have a key role in modulating their activity as regulators of immune cell function. Thus, Siglecs help immune cells to distinguish between self and non-self, whereas sialylated pathogens -by coating themselves with these self-like ligands -can target Siglecs to downregulate immune cell responses and escape immune surveillance [19] [20] [21] [22] [23] . The binding of Siglecs to their ligands has a variety of effects on immune cell function, as illustrated in FIG. 1 (which will be referred to in the context of specific examples throughout this Review). For example, cis interactions of Siglecs with ligands on the same cell are important for regulating the signalling functions of Siglecs (FIG. 1a,b) , and this was elegantly demonstrated for B cells using knock-in mutations of the sialic acidbinding sites of CD22 and Siglec-G 24, 25 . These studies indicated that cis-binding ligands sequester CD22 from its association with the B cell receptor (BCR), and instead promote the association of Siglec-G with the BCR; thus, Siglec-G and CD22 exert opposing effects on setting a threshold for B cell signalling. Trans interactions of Siglecs with soluble glycoconjugates (FIG. 1c,d ) or ligands that are expressed on other cells (FIG. 1e,f) can also modulate signalling. For most Siglecs, the precise oligosaccharide ligands and the protein or lipid carriers that present these to Siglecs remain to be elucidated.
In this Review, we present the recent progress in our understanding of the role of Siglecs in immune cells in the context of infectious disease, lung inflammation, autoimmunity and cancer. In particular, we describe how the interactions of Siglecs and their carbohydrate ligands can modulate cell-cell interactions and the association of the Siglecs with signalling receptors. We also summarize current efforts to develop therapeutics for the treatment of human disease that target Siglecs and exploit their properties. Owing to space constraints, we are unable to provide an in-depth review of other aspects of Siglec structure, evolution and function (for additional information on this topic, see REFS 3, [26] [27] [28] [29] .
Siglecs and infection
The mammalian immune system has evolved highly sophisticated mechanisms to recognize and respond to a diverse array of pathogens, and to eliminate them. of FIG. 2a) .
Siglec-G expression is upregulated on macrophages after infection by RNA viruses -such as vesicular stoma titis virus (VSV) or Sendai virus -but not DNA viruses or bacteria 41 . This upregulation leads to the Box 1 | Siglec-15 regulates the differentiation of osteoclasts
Osteoclasts have a crucial role in bone resorption and are therefore a primary target in osteoporosis 129 . Although osteoclasts are not considered to be part of the immune system, they are derived from a monocyte precursor following stimulation by receptor activator of nuclear factor-κB ligand (RANKL; also known as TNFSF11) 130 . Siglec-15 -which is highly conserved in vertebrates 131 -is constitutively expressed in osteoclasts 132, 133 , and mice lacking Siglec-15 develop mild osteopetrosis, a condition that is characterized by dense bone 134, 135 . In vitro studies have shown that Siglec-15 forms a complex with DAP12 via a lysine residue in the transmembrane domain to deliver a signal that positively regulates osteoclast differentiation into a multinucleated state 12, [133] [134] [135] . Importantly, this function requires sialic acid binding, as a Siglec-15 mutant that disrupts sialic acid recognition impairs osteoclastogenesis in a manner similar to that seen in Siglec15 -/-cells. Current treatment strategies for osteoporosis -such as bisphosphates or an antibody targeting RANKL 136 -ameliorate disease by inhibiting the breakdown of bone through targeting the osteoclasts. Preclinical development is underway for antibodies targeting Siglec-15. These promote Siglec-15 internalization and lysosomal-mediated degradation, which results in the reduced expression of Siglec-15 on osteoclast precursor cells and impaired osteoclastogenesis 12 . Targeting Siglec-15 may therefore lead to novel therapies for treatment of osteoporosis. 
Cis interactions
Binding of Siglec ligandssuch as sialic acid-containing glycans that are commonly found on glycoproteins and glycolipids -that occur on the same Siglec-expressing cell.
Trans interactions
Binding of Siglec ligandssuch as sialic acid-containing glycans that are commonly found on glycoproteins and glycolipids -that occur on opposing cells that are contacted by the Siglec-expressing cell.
B cell receptor
(BCR). On naive B cells, the BCR complex is composed of membrane form of IgM along with Igα (also known as CD79A) and Igβ (also known as CD79B), which initiate BCR signalling through proximal signal components.
Retinoic acid-inducible gene I
(RIG-I). A pattern recognition receptor that has an intricate role in immunity against RNA viruses. RIG-I directly recognizes double-stranded RNA and triggers an antiviral response.
SHP2-and CBL-dependent ubiquitylation and proteosomal degradation of retinoic acid-inducible gene I (RIG-I), and suppression of the interferon-β (IFNβ) response (FIG. 2b) . This negative feedback pathway seems to be exploited by RNA viruses, as VSV-infected mice lacking Siglec-G show decreased viral titres, reduced mortality and increased IFNβ production 41 . Interestingly, this effect of Siglec-G on VSV-triggered IFNβ does not require CD24 and is unaffected by sialidase treatment of the macrophages 41 , which suggests that it is sialic acid independent. The constitutive tyrosine phosphorylation of Siglec-G in macrophages that is observed following VSV infection may be sufficient to recruit and activate SHP2-dependent signalling pathways without a requirement for sialic acid ligation 41 .
Interaction of Siglecs with bacteria. Several human bacterial pathogens can display sialic acid-based ligands for Siglecs, including Neisseria meningitidis, Haemophilus influenzae, Campylobacter jejuni, Pseudomonas aeruginosa and GBS
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. So far, the best evidence that bacterial sialic acids can subvert immune responses via Siglec interactions is from studies of GBS. This bacterium expresses a sialylated capsule (where sialic acid is linked to N-acetyllactosamine; Siaα2,3Galβ1,4GlcNAc) that is recognized by Siglec-9 on human neutrophils and its equivalent Siglec-E in mice 19, 30 (FIG. 2c) . Ligand binding of Siglec-9 suppresses the neutrophil oxidative burst and extracellular trap formation, and thus contributes to pathogen survival 19 . Following intranasal infection with GBS, Siglec-E-deficient mice produced higher levels of Nature Reviews | Immunology the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-6, but reduced levels of IL-10 (REF. 30). Although this did not affect bacterial numbers, Siglec-E-deficient mice showed reduced bacterial dissemination into the brain and kidneys in a sublethal systemic challenge with GBS, which is consistent with bacterial exploitation of Siglec-dependent inhibitory pathways 30 . Certain GBS strains can also target the paired receptors Siglec-5 and Siglec-14 in a sialic acid-independent pathway via interactions with cell wall-anchored β-protein 5, 31 . Similar to Siglec-9 ligation, Siglec-5 ligation by β-protein suppresses neutrophil killing functions 31 . By contrast, Siglec-14 ligation by β-protein triggers an activation pathway that counterbalances the inhibitory signalling of Siglec-5. Both Siglec-5 and Siglec-14 are expressed on human amniotic epithelium and a SIGLEC14 null polymorphism may influence responses to GBS infection and the frequency of preterm births 5 . Siglec-14 can also interact with H. influenzae in a sialic acid-dependent manner, which leads to increased production of IL-8 and tumour necrosis factor, and further supports a host-protective function of this receptor 7 . In contrast to other Siglecs, sialoadhesin is an extended protein with 17 Ig domains that can capture and internalize pathogens in macrophages 34 . Sialoadhesin also lacks intrinsic signalling motifs and has the potential to contribute to host defence via scavenging functions. Direct support for this was provided by an infection model of GBS in which intravenously injected bacteria were taken up by marginal zone macrophages expressing Siglec1 (which encodes sialoadhesin) 34 (FIG. 2d) . This uptake limited bacterial spread to other sites such as the kidneys, lungs and spleen, and wild-type neutropenic mice had increased survival compared with those that lacked Siglec1. Additional support for a role of sialoadhesin in host protection against sialylated bacteria was obtained in studies on the opportunistic human pathogen C. jejuni, which displays a variety of ganglioside-like structures on lipo-oligosaccharides that can be recognized by sialoadhesin and other Siglecs 35, 42 . Injection of mice with C. jejuni expressing ganglioside GD1a-like ligands for sialoadhesin triggered a myeloid differentiation primary response protein 88 (MYD88)-dependent pro-inflammatory cytokine and type I IFN response that was lost in Siglec1 −/− mice 35 (FIG. 2e) . As sialoadhesin strongly promotes macrophage phagocytosis of C. jejuni in this system 35 , crosstalk with TLRs possibly explains these observations. In addition to expressing Siglec ligands on lipo-oligosaccharides, the C. jejuni flagella display pseudaminic acid, which is a sugar that is highly related to sialic acid. A recent study demonstrated that Siglec-10 expressed on human DCs can interact with this sugar and trigger IL-10 production via unknown mechanisms 43 (FIG. 2g) . This may be important for modulation of gut inflammatory responses to this and other enteric pathogens.
Siglecs as receptors for enveloped viruses.
Enveloped viruses, such as HIV and the porcine reproductive and respiratory syndrome virus (PRRSV), are coated with sialic acids that can be recognized by sialoadhesin on macrophages, which promotes uptake and infection 31 . It was recently found that the presence of host cell-derived ganglioside GM3 into the membrane of HIV is required for infection of in vitro-matured DCs, and two research groups independently showed that sialoadhesin is the major receptor for GM3 that delivers HIV to endosomal compartments to promote trans-infection and dissemination of HIV to T cells 44, 45 (FIG. 2f) . A key question to be addressed is whether this pathway has an important role in HIV infection and spread in vivo, as sialoadhesin is not normally expressed on DCs but is restricted to subsets of inflammatory monocytes and tissue macrophages 21 . In this regard, HIV can also interact with other Siglecs -including Siglec-3, Siglec-5, Siglec-7 and Siglec-9 -via sialylated gp120, which also promotes infection of macrophages 46 .
In conclusion, although Siglecs have probably evolved to regulate host immune responses via the recognition of self glycans, an increasing number of studies indicate that sialylated pathogens target Siglecs to modulate immune cell function, which can contribute to pathogenicity and survival within the host.
Siglecs in inflammatory lung diseases
Chronic inflammatory diseases of the lungs, such as allergic asthma and chronic obstructive pulmonary disease (COPD), cause progressive damage to lung tissue. Although the mechanisms differ across inflamma tory lung diseases, innate immune cells such as eosinophils, mast cells, neutrophils and macrophages have established roles in disease pathology [47] [48] [49] [50] [51] (TABLE 1) .
Accumulating evidence suggests that Siglecs have a role in determining the degree of tissue damage that is caused by these cells, and therefore Siglecs may be attractive targets for the treatment of inflammatory lung diseases.
Allergic asthma. Eosinophils, mast cells and basophils are granule-containing cells that have a dominant role in allergic asthma 52, 53 . Siglec-8 is specifically expressed on eosinophils in humans, whereas mouse eosinophils and alveolar macrophages express an isofunctional paralogue, Siglec-F, that has a similar but distinct specificity for sialylated ligands, as described below [54] [55] [56] . Both of these Siglecs have ITIMs 3 , and polymorphisms in the gene encoding Siglec-8 correlate with increased susceptibility to asthma 57 . Insights into the regulatory role of Siglec-8 stem from the observation that crosslinking by antibodies or polymeric glycan ligands causes apoptosis of eosinophils [58] [59] [60] . Surprisingly, this Siglec-8-induced apoptosis is enhanced by IL-5, which normally promotes eosinophil survival 58, 61 . These findings suggest that the ligation of Siglec-8 by natural ligands may regulate the frequency of eosinophils in tissues 29, 58 (FIG. 1e) . For mouse eosinophils, ligation of Siglec-F with antibodies also causes apoptosis; however, the effect is modest and seems to be mediated by a different mechanism 61 , which suggests that information gleaned from disease models involving Siglec-F should be interpreted with caution when considering its relevance to Siglec-8 and human disease 56, 57 .
DC or macrophage DC
Siglec-10
Siglec-E GBS Nature Reviews | Immunology 
Alzheimer's disease
The most common form of dementia occurring as a result of plaque deposition and neurofibrillar tangles in the brain.
Amyloid-β
A peptide that is proteolytically processed from amyloid precursor protein and that can aggregate to form oligomers and give rise to the amyloid plaques found in the brains of patients with Alzheimer's disease.
The specificity of Siglec-8, as assessed by glycan microarray analysis, has revealed high specificity for a sialylated-sulphated glycan epitope, NeuAcα2,3[6S] Galβ1,4GlcNAc 56, 62, 63 . Although this specificity is shared with Siglec-F, the mouse paralogue also binds with lower affinity to ligands without the sulphate 13, 56, [62] [63] [64] [65] . In mouse models of ovalbumin-induced airway inflammation, Siglec-F ligands are dramatically upregulated on epithelial cells and mucins 62, [65] [66] [67] [68] . In most, but not all, models of lung allergy, mice deficient in either Siglec-F or its ligands (for example, St3gal3 −/− mice, which lack the gene encoding ST3 β-galactosidase α-2,3-sialyltransferase 3) exhibit strongly enhanced eosinophil infiltration 62, [67] [68] [69] . These results support a working model in which trans-activation of Siglec-F by ligands on an opposing cell (FIG. 1e) or by polymeric mucin (FIG. 1c) is sufficient to dampen eosinophil activation or induce apoptosis to moderate eosinophil accumulation. However, it may not be so simple, as Siglec-F-deficient mice exhibit increased accumulation of eosinophils in tissues other than the lungs in a model of allergic airway inflammation 66 .
Chronic and acute lung inflammation. Neutrophils also have a major role in the pathology of acute and chronic lung inflammatory diseases, such as COPD 48, 50 . Human neutrophils express two inhibitory Siglecs, Siglec-5 and Siglec-9, as well as the activating Siglec-14, whereas mouse neutrophils express Siglec-E and low levels of Siglec-F, which are both inhibitory 3 . In a model of lipopolysaccharide-induced lung inflammation, Siglec-E-deficient mice showed enhanced neutro phil migration into lung tissue that was blocked by antibody specific for the β2 integrin CD11b 70 . Neutrophils adherent to the CD11b ligand fibrinogen exhibited enrichment of Siglec-E at the adhesion foci on fibrinogen-coated slides. Moreover, outside-in signalling by CD11b, including phosphorylation of SYK and p38 mitogen-activated protein kinases, was enhanced in Siglec-E-deficient neutrophils. Prior treatment of fibrinogen with sialidase enhanced outside-in signalling in wild-type but not Siglec-E-deficient neutrophils. A follow-up study has shown that, paradoxically, Siglec-E promotes the β2 integrin-dependent production of reactive oxygen species by neutrophils in vitro and in vivo, and this is required for its suppression of neutrophil recruitment to the lungs 71 .Taken together, the results suggest that CD11b-mediated outside-in signalling may be modulated both negatively and positively by Siglec-E through sialic acid-dependent recruitment to the sites of contact with its ligand fibrinogen 70 (FIG. 1f) . Although not a Siglec, there are interesting parallels with another neutrophil inhibitory receptor, paired immunoglobulin-like type 2 receptor-α (PILRα), which mediates high-affinity sialic acid-dependent interactions with cis ligands, and suppresses neutrophil β2 integrin signalling and chemotactic responses 72 . A recent report has identified a null allele polymorphism of the gene encoding neutrophil-activating Siglec-14 (REF. 7). Patients with COPD who are homozygous for this null allele had fewer inflammatory exacerbations than patients expressing the wild-type allele, which suggests that Siglec-14 may promote inflammatory sequelae caused by neutrophils. Whereas the roles of Siglecs continue to emerge, the forgoing examples illustrate that they influence inflammatory lung diseases as a consequence of their intrinsic roles in the regulation of the cells that mediate immune responses in the lungs.
Siglecs in neurodegeneration
In the central nervous system, microglia are specialized resident macrophages that are derived from yolk sac precursors and bone marrow monocytes. They are thought to have a protective role through the removal of senile plaques and damaged neurons, but in some conditions they can also exacerbate inflammatory conditions and have neurotoxic effects 73 . Microglia express a number of Siglecs -including CD33, Siglec-11 and Siglec-16 in humans, and CD33, Siglec-E, Siglec-F and Siglec-H in mice -several of which have been associated with pathology in neurodegenerative diseases 8, [74] [75] [76] [77] [78] . Genome-wide association studies have recently identified variants of CD33 as a major risk factor for Alzheimer's disease [79] [80] [81] . The risk allele of a polymorphism in CD33 was associated with increased expression of CD33 on microglial cells and correlated with decreased in vitro uptake of toxic amyloid-β plaques [74] [75] [76] . These data have led to a model in which CD33 is proposed to negatively regulate the ability of microglia to phagocytize toxic amyloid-β. Furthermore, an additional protective allele, that is co-inherited with the aforementioned risk allele, produces a CD33 protein without its V-set domain, which suggests that ligand binding may have a role in suppressing plaque uptake 75, 82 . Although CD33-deficient mice also have a diminished incidence of amyloid-β plaque pathology 74 , the mouse may not provide a good model in which to study the role of CD33 in human disease. In contrast to human CD33, which is an inhibitory Siglec, mouse CD33 lacks a cytoplasmic ITIM and exists in two splice variants. These variants are predicted to associate with DAP12 owing to the presence of a lysine residue within the transmembrane region, and thus they are thought to mediate activatory functions. A better understanding of these processes is needed to define the basis for the association of the CD33 risk allele with Alzheimer's disease.
In microglia, Siglec-11 and Siglec-E are constitutively expressed and they can have neuroprotective effects by recognizing trans sialic acid ligands on neuronal cells (FIG. 1f) , which leads to the suppression of inflammatory responses by preventing the excessive uptake of apoptotic neuronal debris 78 . Expression of Siglec-F and Siglec-H under inflammatory conditions has also been proposed to regulate microglial cell function 78 . Although recent studies show that several Siglecs have the potential to have preventative or causative roles in neuro degeneration, further studies are needed to gain a clearer understanding of how Siglecs regulate the function of resident and activated microglia and inflammatory monocytes in neurodegenerative diseases. 
Siglecs in autoimmunity
The failure of the immune system to correctly distinguish self from non-self is one hallmark of autoimmunity. Siglecs are appropriately positioned to aid the immune system in self-recognition because they recognize sialoside ligands that are present on interacting cells and can dampen cellular activation (FIG. 1f) . Insights into the circumstances in which Siglec-ligand interactions participate in mechanisms of self-tolerance are beginning to emerge. In particular, recent studies demonstrate an important role for the Siglecs expressed by B cells in suppressing immune responses to self-antigens and preventing autoimmunity, and suggest that Siglecs may also directly or indirectly regulate T cell responses that are relevant to self-tolerance.
The role of Siglecs in self-tolerance. Pathogenic autoantibodies arise from the inappropriate stimulation and expansion of self-reactive B cells 83 . Under healthy conditions, such autoreactive B cells are purged or silenced through mechanisms of B cell tolerance 84 . The Siglecs expressed by B cells contribute to mechanisms of B cell tolerance by acting as inhibitory co-receptors of the BCR 26 . In humans, peripheral naive B cells express CD22 and Siglec-10, whereas mouse B cells express CD22 and the Siglec-10 orthologue, Siglec-G. The importance of the combined actions of CD22 and Siglec-G in B cell tolerance have been clearly demonstrated in mice lacking both Siglecs, which develop systemic autoimmunity as they age 85 , and in mice deficient in Siglec-G alone, which have an earlier onset and increased severity of lupus-like and autoimmune disease 86 . 87 have a considerable, yet complex, influence on the threshold for B cell activation. A recent study showed that B cells from CD22-deficient mice and mice bearing a mutant of CD22 that cannot interact with sialic acid, are hyperresponsive and hyporesponsive to BCR stimulation, respectively 25 , which supports earlier observations that cis CD22 ligands on the B cell limit the association of CD22 with the BCR 3,88,89 (FIG. 1b) . By contrast, another recent report showed that a point mutation in the gene encoding Siglec-G that ablates sialic acid binding leads to decreased association of Siglec-G with the BCR and a decreased threshold for B cell activation 24, 25 . In humans, mutations in the gene encoding sialic acid 9-O-acetyl esterase (SIAE) have been correlated with autoimmunity 90 . Since sialic acid esterases remove an O-acetyl group from sialic acid, which can otherwise block Siglec binding, sialic acid esterase deficiency lowers the levels of Siglecs ligands. Furthermore, mice deficient in the enzyme cytidine monophosphate NeuAc hydroxylase (CMAH) are unable to convert NeuAc to N-glycolyl-neuraminic acid (NeuGc; the preferred sialic acid for mouse Siglecs) 91 and they exhibit a hyperactive B cell phenotype 91, 92 . This phenotype has been attributed to the abrogation of cis ligand interactions between CD22 and the BCR. This interpretation, however, needs to be re-evaluated in the context of the inhibitory activities of both CD22 and Siglec-G, which have overlapping ligand specificities (TABLE 1). Given that both CD22 and Siglec-G can independently modulate the activity of the BCR [24] [25] [26] , changes in the expression of cis ligands on the B cells have the potential to modulate BCR signalling through either of these Siglecs. It is also notable that dramatic remodelling of the Siglec ligands expressed by B cells occurs in the germinal centre in both mice 91 and humans 93 , yet the functional consequence of this remodelling remains largely unexplored.
Interactions of B cell Siglecs with their cis ligands
Although cis ligands set a threshold for the interaction between CD22 and the BCR, several studies have shown that they do not preclude interactions with trans ligands on other cells [94] [95] [96] . A recent report demonstrates that trans ligands of CD22 on blood vessel endothelial cells are involved in the trafficking of mature B cells to Peyer's patches 96 . Moreover, recent studies have demonstrated that trans CD22-ligand interactions can have a marked influence on the regulation of BCR signalling through CD22. Several studies have used polymers or liposomes displaying both antigen and a Siglec ligand to demonstrate that drawing CD22 or Siglec-G together with the BCR has a strong inhibitory effect on BCR signalling [97] [98] [99] [100] [101] (FIG. 1c) . Co-presentation of antigens with ligands of CD22 or Siglec-G results in strong inhibition of B cell activation, inhibition of tonic BCR signalling through the AKT-mediated survival pathway, apoptosis of the antigen-reactive B cell and consequently, the induction of B cell tolerance 98, 99 . These principles were also shown to apply to cell-surface antigens that are co-displayed with endogenous sialoside ligands of the B cell Siglecs 99, 149 . Taken together, these findings suggest that CD22 and Siglec-G help to enforce peripheral B cell tolerance to membrane antigens by a mechanism involving their recruitment to the immunological synapse through recognition of sialylated glycans on the cell displaying antigen, which results in apoptosis of the antigenreactive B cell 99, 149 (FIG. 3) . In this regard, as CD22 and Siglec-G recognize a different spectrum of ligands 97 , and independently suppress B cell activation 98 , they provide B cells with the potential to recognize self ligands regardless of the types of sialosides that are present on the surface of cells.
Impact of Siglecs on effector T cells.
Several autoimmune disease models have revealed a pro-inflammatory role for sialoadhesin on macrophages in promoting the activation of CD4 + and CD8 + T cells. In an experimental autoimmune encephalomyelitis model, regulatory T (T Reg ) cells were shown to express high levels of sialo adhesin ligands following activation, and their engagement with sialo adhesin on macrophages led to the suppression of T Reg cell expansion and the exacerbation of disease 102 . Similarly, a subset of effector T cells also upregulates sialoadhesin ligands upon activation, leading to T cell apoptosis 103 (FIG. 1e) . Hence, the upregulation of sialoadhesin ligands on different T cell subsets seems to have a role in sialoadhesin-dependent immunoregulation.
Although it is generally accepted that the majority of T cells in humans and mice lack Siglec expression, a recent study has proposed that a subset of CD52 hi suppressor T cells secretes soluble CD52 that presumably binds to Siglec-10 and suppresses the activation of T cells that promote autoimmune diseases such as type 1 diabetes 104 . The depletion of CD52 hi T cells from splenocytes injected into diabetes-prone non-obese diabetic severe combined immunodeficiency (NOD-SCID) mice accelerated the onset of disease 104 . Although a role of Siglec-10 in this study was inferred from the use of blocking antibodies, further studies are needed to characterize the expression of Siglec-10 on T cells and to determine the mechanism by which it suppresses T cell activation.
Siglecs in immune surveillance of cancer Siglecs have long been associated with cancer; CD22 and CD33 were discovered as specific markers of B cell lymphomas and myeloid leukaemias long before they were identified as members of the Siglec family 105, 106 . Several recent reports suggest that Siglec deficiencies can increase the potential for the generation of lymphomas and leukaemias 107, 108 . Moreover, in keeping with their roles in aiding immune cells to distinguish between self and non-self, a role for Siglecs in the regulation of immune surveillance of cancer is emerging. This role is particularly relevant in light of the well-documented alterations of glyco sylation, including increased sialylation, that occur in many cancers 109 . Cancer cells must evade attack by innate lymphoid natural killer (NK) cells that can recognize transformed cancer cells as 'altered self ' and initiate innate immune responses. NK cells distinguish normal cells from altered cells through an array of activatory and inhibitory receptors that recognize signatures of self and nonself 110 . The inhibitory receptors include Siglec-7, which is highly expressed on most NK cells, and Siglec-9, which is expressed only by a subset of NK cells 111 . It has been
shown that the recognition of sialic acid-containing ligands by Siglec-7 on the surface of a target cell draws it into the site of cell contact to dampen NK cell activation 112, 113 (FIG. 1f) . Previously, it was speculated that cancer cells upregulate ligands of Siglec-7 to exploit this mechanism of silencing NK cells 113 . Indeed, as revealed by two recent studies 111, 112 , the expression levels of Siglec-7 and Siglec-9 ligands are greatly increased on a variety of cancer cells, which decreases their susceptibility to NK cell killing. Intrinsic to these findings is that the destruction of Siglec ligands by sialidase treatment of the cancer cells abrogates an inhibitory effect through Siglec-7, which also holds true in vivo using mice reconstituted with human NK cells 111 . Heavily glycosylated mucins are commonly produced by cancer cells and can, in principle, modulate immune surveillance by binding to Siglecs (FIG. 1c,d ). Human tumour-produced mucins have been found to bind to Siglec-9 on NK cells, B cells, monocytes and DCs, and to downregulate immune cell responses 38, 114 . Similarly, when administered to mice, tumour mucins that bind to CD22 deplete marginal zone B cells in a manner similar to that seen in mice bearing tumours 115 . Thus, soluble mucins produced by tumours may also contribute to the escape of cancer cells from immune surveillance.
As seen in these examples, Siglecs effectively reduce innate immune responses against cancer cells by downregulating the responses of immune cells that express them following recognition of sialoside ligands on the cancer cell itself or the soluble mucins that are produced by the cancer cell.
Siglecs as therapeutic targets
Siglecs are increasingly being recognized as targets for development of immunotherapeutics owing to their highly restricted expression in the immune system and their differential expression by various immune cell subsets 28, 53, 116 (FIG. 4) . Siglec-specific antibodies have been in clinical development for leukaemia and lymphoma for more than 20 years, providing a wealth of experience of using antibodies as targeting agents 105, 106 . More recently, glycan ligand-decorated nanoparticles have shown promise as an alternative way to target Siglec-expressing cells 11, 117, 118 . The majority of the Siglecs are endocytic receptors 3,9,10,13 , which makes them candidates for targeted therapeutics that involve the delivery of cytotoxic or immunomodulatory agents into the target cell 105, 106, 117 ( FIG. 4a) . This section reviews the current status of agents targeting Siglecs that are in clinical development and the efforts to develop alternative strategies that exploit Siglecs on immune cells for therapeutic purposes.
Cell depletion therapy for lymphomas and leukaemias. A CD33-specific immunotoxin, gemtuzumab ozogamicin (Mylotarg; Pfizer), was approved in the United States in 2002 for the treatment of acute myeloid leukaemia. Although it was withdrawn owing to concerns about its efficacy and safety in 2010, it continues to be actively pursued for the treatment of subsets of patients with acute myeloid leukaemia 119 , and there are numerous ongoing clinical trials with CD22-specific Nature Reviews | Immunology and CD33-specific antibody-based therapies for B cell lymphomas and myeloid leukaemias 105, 106, 116, 120 . Most of the antibody-based therapeutics are immunotoxins, comprising CD22-specific or CD33-specific antibodies conjugated to calicheamicin (for example, gemtuzumab ozogamicin and inotuzumab ozogamicin) or bacterial protein toxins (such as moxetumomab pasudotox), which rely on the endocytic activity of the Siglec to internalize the toxin into the target cell (left panel of  FIG. 4a) . Other strategies are radiolabelled antibodies or naked antibodies that kill leukaemia cells by irradiation and by inducing antibody-dependent cellular cytotoxicity or complement-induced cytotoxicity, respectively, and these are used in combination with standard chemotherapeutics (for example, epratuzumab and Y 90 -epratuzumab) 106 . A promising alternative strategy proposed for B cell lymphomas is to use chemotherapeutic-loaded nanoparticles decorated with glycan ligands that actively target CD22 on lymphoma cells 106, 117 (right panel of  FIG. 4a) . Doxorubicin-loaded liposomal nanoparticles decorated with glycan ligands of CD22 have shown remarkable efficacy in murine tumour models of B cell lymphoma compared to liposomal formulations without the ligand 117 . A potential advantage of this approach is that ligands are released from CD22 in the endosomal compartment, which enables ligand-targeted cargo to be 'pumped' into the cell as CD22 recycles from the surface 9 . The progress in the development of Siglec-targeted therapies for treatment of lymphomas and leukaemias has drawn attention to Siglecs as targets for treatment of immune-mediated diseases.
Cell depletion therapy for allergic inflammation. The discovery that the ligation of Siglec-8 causes apoptosis of eosinophils has stimulated interest in Siglec-8 as a therapeutic target in inflammatory diseases involving pathology induced by eosinophils 53, [58] [59] [60] 121 . The impact of eosinophil depletion on allergic inflammatory diseases has been explored most directly in mouse models using antibodies specific for Siglec-F, which effectively deplete eosinophils from the blood and tissues 122 . Using this approach, the depletion of eosinophils has been documented to substantially reduce pathology in models of allergic rhinitis 123 , oesophageal eosinophilia 124 and allergen-induced eosinophil airway remodelling 125 . A similar approach has been used to demonstrate a beneficial effect of eosinophil depletion on allergen-induced intestinal inflammation 125 .
Antigen targeting to antigen-presenting cells. Siglecs have been used as targets for the delivery of antigens to antigenpresenting cells to induce a more efficient immune response. Proof of principle for this strategy has been documented in vivo for targeting antigens to sialoadhesinpositive macrophages using sialoadhesin-specific antibodies coupled to protein antigens (left panel of FIG. 4a) , or liposomes bearing glycan ligands of sialoadhesin carrying protein or glycolipid antigens (right panel of FIG. 4a) , which result in enhanced activation of CD4 + T cells and NKT cells, respectively 10, 11, 126, 127 . Although the efficiency of antigen delivery may not, by itself, be sufficient to warrant a targeted approach, targeted nanoparticles have the potential to incorporate adjuvants and other agents to elicit a desired immune response.
Induction of antigen-specific B cell tolerance.
Immunotherapies designed to generally suppress immune responses have been useful in the areas of autoimmunity, allergy and transplantation. However, suppressing the entire adaptive immune system also leads to decreased immunity to pathogens; hence, there is a need for methods that suppress immune responses to the pathogenic antigens but preserve protective immunity. The induction of antigen-specific tolerance has enormous therapeutic potential, but also presents major challenges. As described above, co-presenting antigen and ligands of CD22 or Siglec-G on the same surface can have a marked inhibitory effect on B cells (FIG. 3) . Liposomal nanoparticles that display both antigen and a Siglec ligand were found to induce tolerance through promoting the apoptosis of the antigen-reactive B cells 98, 99 (FIG. 4b) . These Siglec-engaging tolerance-inducing antigenic liposomes (STALs) were investigated for their ability to prevent the production of inhibitory antibodies specific for the coagulation factor FVIII, which is a well-documented problem for 20-30% of patients with haemophilia A that receive biotherapeutic FVIII as replacement therapy 99 . STALs bearing FVIII and CD22 ligands were shown to successfully induce tolerance in FVIII-deficient mice, which prevented high titres of FVIII-specific antibodies from developing after a challenge with immunogenic liposomes and, consequently, FVIII could be successfully administered to prevent bleeding 99 . By contrast, administration of FVIII failed to prevent bleeding in mice that did not receive STALs prior to the challenge. The results from this study indicate the potential for using such strategies to induce B cell tolerance in therapeutic settings.
As evident from this Review, the roles of Siglecs in the regulation of immune cell function are beginning to emerge, revealing insights into their impact on mechanisms of diseases that involve the cell types that express them. This has led to the recognition of Siglecs as targets for cell-specific therapies involving the delivery of therapeutic cargo or modulation of immune cell function.
Concluding remarks
Since the discovery of the Siglec family nearly 20 years ago, the roles of Siglec-ligand interactions in the regulation of immune cell function are beginning to emerge. Sialic acid-containing glycans are effectively self epitopes and by contacting them, Siglecs can help immune cells to distinguish between self and non-self. These interactions create context-specific biology that can either sequester or colocalize the regulatory Siglec with activatory or inhibitory receptors, and thereby regulate the activation status of a cell. As a result of their regulatory activity, Siglecs have an important role in disease processes and have been recognized as therapeutic targets.
Despite this progress, the biological context in which most Siglecs modulate immune cell function is still poorly understood. In particular, although their roles as inhibitory or activatory co-receptors are well documented, the precise signalling receptors and signalling pathways that they modify are still not known for most of them. Moreover, even for well-studied Siglecs, such as CD22, much is yet to be learned. For example, although the role of CD22 in modulating the activity of the BCR has been extensively studied, CD22 also affects TLR signalling in B cells, and has been implicated in trafficking of mature B cells to Peyer's patches 85, 96, 128 . Applying such considerations to other less studied Siglecs emphasizes that much is yet to be learned about this family of receptors, and future investigation should offer major new insights into their biology and roles in regulating immune cell function. A deeper understanding of the roles of Siglecs in immune cell function will accelerate the pace of exploiting that knowledge for the development of agents with which to treat diseases.
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